홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ANVS
#3492
Annovis Bio, Inc.
2.6
9
-2.54%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-2.54%
월간 변동
-9.12%
6달 변화
+14.47%
년간 변동율
+46.20%
이전 종가
2.7
6
Open
2.6
6
Bid
Ask
Low
2.6
6
High
2.6
9
양
28
마켓
주식
헬스케어
ANVS
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
6.95 M
8.16 M
8.22 M
11.01 M
19.49 M
—
Valuation ratios
Enterprise value
44.3 M
97.84 M
78.36 M
202.69 M
87.46 M
159.19 M
Price to earnings ratio
—
-9.25
-4.19
-3.04
-2.18
-6.06
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
-14.68
-6.12
-4.27
-2.81
-6.32
Price to book ratio
—
3.01
3.74
-22.04
6.61
8.36
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.67
-0.31
-0.7
-5.51
-1.77
-1.34
Return on equity %
-0.72
-0.33
-0.89
7.25
-2.64
-1.75
Return on invested capital %
-692.95 K
-3.03 M
—
-278.95 K
-5 291.27
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
14.04
30.54
4.68
2.39
2.83
22.32
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-1.2
-2.12
-4.43
-1.79
-1.6
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
5.99
3.48
0.64
0.87
3.88
Net current asset value per share
—
6.03
4.41
1.13
0.9
3.98
Tangible book value per share
—
5.83
3.47
-0.86
0.76
3.83
Working capital per share
—
5.83
3.47
0.66
0.58
3.17
Book value per share
—
5.83
3.47
-0.86
0.76
3.83
뉴스
아노비스 바이오, 2026년 1월 파킨슨병 장기 약물 연구 개시
Annovis Bio to launch long-term Parkinson’s drug study in January
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
Monday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale Tops
Annovis Bio 이사 Hoffman, 193,794달러 상당 주식 매수
Annovis Bio director Hoffman buys $193,794 in shares
Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling
아노비스 바이오 이사 Hoffman, ANVS 주식 69.9천 달러 매입
Annovis Bio director Hoffman buys $69.9k in ANVS stock
Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS)
Annovis Bio’s phase 3 Alzheimer’s trial reaches 25% completion
Annovis Bio raises $3.4 million in registered direct offering